Updated Results Of Destiny-Breast03: T-Dxd Vs T-Dm1 In Metastatic Her2+ Breast Cancer

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer

DESTINY-Breast03: T-DXd is superior to T-DM1 in HER2+ metastatic breast cancer

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1

DESTINY-Breast03: safety follow-up results

DESTINY-Breast03: practice-changing results from ESMO 2021

Highlights from ESMO: DESTINY-Breast03

SABCS 2022: DESTINY-Breast02 + DESTINY-Breast03

Choosing between tucatinib and T-DXd in HER2+ breast cancer

Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast Cancer

Comparing and sequencing T-DM1 and T-DXd in HER2+ breast cancer

#ESMO21 Expert Video Report on HER2-positive metastatic breast cancer

European Society for Medical Oncology (ESMO)

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

DESTINY-Breast02: high levels of efficacy of T-DXd in previously treated HER2+ breast cancer

Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups

DESTINY-Breast04: T-DXd for patients with HER2-low mBC

SABCS 2022: Updated survival results of the randomized, phase 3 study DESTINY-Breast03 + Q & A

Trastuzumab deruxtecan shows benefit in patients with HER2 + mBC

GS3-01: "Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic..."

San Antonio Breast Cancer Symposium